Literature DB >> 205647

Neostigmine-induced alterations at the mammalian neuromuscular junction. I. Muscle contraction and electrophysiology.

T N Tiedt, E X Albuquerque, C S Hudson, J E Rash.   

Abstract

The effects of single and repetitive injections of neostigmine on neuromuscular physiology were examined in rat extensor digitorum longus muscles. The characteristic facilitation of neuromuscular transmission associated with acute anticholinesterase treatment was accompanied by significant pre- and postsynaptic alterations in neuromuscular transmission. Three days of neostigmine treatment caused a decrease in indirectly and directly elicited muscle contraction. Miniature end-plate potential amplitude and frequency, end-plate potential amplitude, junctional acetylcholine sensitivity and quantal content of nerve-evoked end-plate potentials were also decreased by this treatment. By 22 to 25 days of continued treatment, the decreased rate of transmitter release had returned almost to normal, whereas the alterations of the postsynaptic membrane persisted for as long as 106 days. Alterations were also found in the muscle action potential and in certain passive electrical properties of the extrajunctional muscle membrane. In addition, many of the physiological changes were correlated directly with the morphological changes observed in rats treated similarly. We conclude that neostigmine treatment in rats in therapeutic doses has deleterious effects on neuromuscular physiology and neuromuscular ultrastructure. Although the pattern of these changes is not identical with that seen in rabbit and human myasthenia gravis, the neostigmine treatment used in patients with myasthenia gravis may contribute in part to the neuromuscular alterations observed in this disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 205647

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  The effect of chronic neostigmine treatment on channel properties at the rat skeletal neuromuscular junction.

Authors:  M Gwilt; D Wray
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

3.  Pathophysiological studies of neuromuscular function in subacute organophosphate poisoning induced by phosmet.

Authors:  J L Good; R K Khurana; R F Mayer; W M Cintra; E X Albuquerque
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-03       Impact factor: 10.154

Review 4.  Immunopathology of acetylcholine receptors in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Springer Semin Immunopathol       Date:  1982

5.  Receptor-mediated presynaptic facilitation of quantal release of acetylcholine induced by pralidoxime in Aplysia.

Authors:  P Fossier; G Baux; B Poulain; L Tauc
Journal:  Cell Mol Neurobiol       Date:  1990-09       Impact factor: 5.046

6.  Skeletal muscle calpain acts through nitric oxide and neural miRNAs to regulate acetylcholine release in motor nerve terminals.

Authors:  Haipeng Zhu; Bula Bhattacharyya; Hong Lin; Christopher M Gomez
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

7.  Elucidation of the mechanism and site of action of quinuclidinyl benzilate (QNB) on the electrical excitability and chemosensitivity of the frog sartorius muscle.

Authors:  G G Schofield; J E Warnick; E X Albuquerque
Journal:  Cell Mol Neurobiol       Date:  1981-06       Impact factor: 5.046

8.  The behavioral effects of phencyclidines may be due to their blockade of potassium channels.

Authors:  E X Albuquerque; L G Aguayo; J E Warnick; H Weinstein; S D Glick; S Maayani; R K Ickowicz; M P Blaustein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

9.  Influence of neostigmine treatment on embryonic development of acetylcholine receptors and neuromuscular junctions.

Authors:  G S Sohal; W R Boydston
Journal:  J Cell Biol       Date:  1982-09       Impact factor: 10.539

10.  β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.

Authors:  An E Vanhaesebrouck; Richard Webster; Susan Maxwell; Pedro M Rodriguez Cruz; Judith Cossins; James Wickens; Wei-Wei Liu; Hakan Cetin; Jonathan Cheung; Hayley Ramjattan; Jacqueline Palace; David Beeson
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.